Q-omics provides the consensus-scored CCDC167 profile across patient tissues and cancer cell-line models. CCDC167 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCDC167 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, CCDC167 RNA expression shows 19,029 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where CCDC167 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC167 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC167 survival associations across molecular data types. CCDC167 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC167 RNA expression–survival associations across cancer types. High CCDC167 expression shows unfavorable associations in KIRP, ACC, LIHC, KIRC, LAML and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCDC167 RNA expression.
This table summarizes CCDC167 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC167. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC167 shows higher tumor expression in KIRC, COAD, BLCA, KIRP, HNSC and LUAD. The KIRC box plot shows higher CCDC167 RNA expression in tumor versus normal tissue (log2 FC = +1.131, t-test p < 0.001).
This table shows molecular features associated with CCDC167 in patient tissues and cancer cell lines. In patient samples, CCDC167 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC167 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
